Source Post
Up 157% in 2025, Is it too Late to Buy Hims Stock? | HIMS STock Analysis |
May 21, 2025
Parkev Tatevosian maintains a buy rating on Hims & Hers Health, citing exceptional revenue growth and a transition to strong positive cash flow. Despite a massive year-to-date rally, he believes the stock remains fairly valued based on its premium performance metrics.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.